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Introduction
In the United States, between 2004 and 2005, soft tis-
sue injuries such as strains, sprains and contusions
each accounted for approximately 18% of initial vis-
its to the emergency department for injuries (1). The
most common sports-related musculoskeletal injury
is ankle sprain (2,3), for which approximately 2 mil-
lion people seek medical treatment each year (3).
Other common soft tissue injuries occur in the elbow
(4) and knee (5).
Use of an analgesic medication, in particular the
judicious use of oral traditional non-steroidal anti-
inﬂammatory drugs (NSAIDs) and cyclooxygenase-2
inhibitors (coxibs), has been shown to be beneﬁcial
in reducing pain and swelling in acute soft tissue
injuries (6,7). NSAID treatment is included in cur-
rent guidelines for the treatment of acute ankle
sprain, which focuses on the reduction of inﬂamma-
tion and pain following injury (8,9). Interest in topi-
cal NSAIDs for this use has been increasing as a
result of growing awareness of the adverse effects
(AEs) associated with systemic NSAIDs and coxibs.
Three topical NSAID formulations, all salts of dic-
lofenac, are approved for use for pain indications in
the United States: diclofenac epolamine topical patch
1.3% (DETP; FLECTOR
  Patch) (10); diclofenac
sodium gel 1% (Voltaren
  Gel) (11) and diclofenac
sodium topical solution 1.5% (Pennsaid
 ) (12).
NSAIDs overview
The consequences associated with pain include nega-
tive effects on quality-of-life and societal costs (13).
Musculoskeletal pain is a common problem often
treated with NSAIDs and coxibs. Postmarketing AE
monitoring of the use of oral NSAIDs and coxibs has
brought the issue of safety to the forefront (13,14).
The beneﬁts of oral NSAID therapy must be weighed
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SUMMARY
Acute pain caused by musculoskeletal disorders is very common and has a signiﬁ-
cant negative impact on quality-of-life and societal costs. Many types of acute pain
have been managed with traditional oral non-steroidal anti-inﬂammatory drugs
(NSAIDs) and selective cyclooxygenase-2 inhibitors (coxibs). Data from prospective,
randomised controlled clinical trials and postmarketing surveillance indicate that
use of oral traditional NSAIDs and coxibs is associated with an elevated risk of
developing gastrointestinal, renovascular and⁄or cardiovascular adverse events
(AEs). Increasing awareness of the AEs associated with NSAID therapy, including
coxibs, has led many physicians and patients to reconsider use of these drugs and
look for alternative treatment options. Treatment with NSAIDs via the topical route
of administration has been shown to provide clinically effective analgesia at the
site of application while minimising systemic absorption. The anti-inﬂammatory and
analgesic potency of the traditional oral NSAID diclofenac, along with its physico-
chemical properties, makes it well suited for topical delivery. Several topical formu-
lations of diclofenac have been developed. A topical patch containing diclofenac
epolamine 1.3% (DETP, FLECTOR
  Patch), approved for use in Europe in 1993,
has recently been approved for use in the United States and is indicated for the
treatment of acute pain caused by minor strains, sprains and contusions. In this
article, we review the available clinical trial data for this product in the treatment
of pain caused by soft tissue injury.
Review Criteria
Information was gathered through a search of
MEDLINE, Derwent Drug File, BIOSIS and EMBASE
databases on diclofenac epolamine topical patch
and diclofenac hydroxyethylpyrrolidine patch, for
publications from 1985 to present, in any
language. Additional sources used in the
development of this article include product
prescribing information and relevant conference
poster presentations.
Message for the Clinic
Interest in topical NSAIDs that provide analgesia
while minimising systemic absorption has increased
as a result of growing awareness of adverse events
associated with systemic therapy. The diclofenac
epolamine topical patch 1.3% (DETP), available in
Europe since 1993, was recently approved in the
United States for topical treatment of acute pain
caused by minor strains, sprains and contusions.
Newly available postmarketing surveillance data
covering approximately 14 years strengthen
available safety data. DETP continues to offer a
viable treatment option in patients with acute pain
caused by minor strains, sprains and contusions.
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cardiovascular events (14), gastrointestinal (GI)
ulceration⁄bleed (15,16) and renal side effects (17).
The potential for GI AEs is an especially important
concern for elderly patients (15,18).
Use of oral NSAIDs has been associated with a sig-
niﬁcantly increased risk of GI complications (19);
among patients in the primary care setting, the prev-
alence of NSAID-associated ulcers was found to be
16% (20). Although less clinically detrimental than
ulcers and GI bleeds, dyspepsia is a far more preva-
lent complication of NSAID therapy, conferring a
signiﬁcant clinical burden (21). Oral NSAID use has
been shown to increase the risk of dyspepsia by
approximately 40% (22); because of this increased
risk, GI co-medications such as proton pump inhibi-
tors are often required (15). In addition, GI AEs,
including nuisance symptoms such as dyspepsia,
upper abdominal pain and general abdominal pain,
are among the most common reasons for discontinu-
ation of oral NSAID therapy (23).
The GI tolerability and favourable systemic toxicity
proﬁle observed with topical NSAIDs may be a result
of low systemic blood concentrations (18,24). Heyn-
eman et al. (25) reviewed both single- and multiple-
dose NSAID absorption studies. After topical NSAID
administration, studies showed that peak plasma lev-
els of the NSAID moiety were less than 10% of those
obtained after oral administration (25). The pharma-
cological action of topical NSAIDs is exerted at the
local level and is not dependent on systemic absorp-
tion (18,24).
Topical agents that are now available include
NSAIDs, counter-irritants (e.g. capsaicin) and local
anaesthetics, such as the lidocaine patch 5%
(24,26). A clear distinction must be made between
incidental absorption from topically applied drugs
and that of transdermally absorbed drugs, whose
action depends on systemic absorption (e.g. fenta-
nyl, nicotine patches) (18,24,27). Although both
types of formulations are applied directly to the
skin, transdermal formulations are speciﬁcally
designed to facilitate drug diffusion through the
various layers of the skin into the systemic circula-
tion (28) with the goal of achieving systemic levels
comparable with those obtained with oral medica-
tions (24). For a topical drug formulation, however,
the site of activity is the tissue directly underlying
the application site, including the soft tissue and
peripheral nerves (24,29). A topical drug uses trans-
cutaneous delivery to penetrate the stratum corne-
um and reach its site of action (18). Serum levels
generally remain relatively low and, consequently,
systemic side effects or drug–drug interactions are
signiﬁcantly less likely (24).
The goal of topical agents is to achieve similar efﬁ-
cacy to oral formulations with potentially lower sys-
temic side effects (24). Penetration studies conﬁrm
that topical NSAIDs reach therapeutic concentrations
underneath the site of application equivalent or
greater to those seen with larger doses of oral
NSAIDs (18,24,25). Another key factor in determin-
ing the effectiveness of topically applied NSAIDs is
their intrinsic pharmacological potency in terms of
cyclooxygenase (COX) inhibition. Those traditional
NSAIDs with a high intrinsic potency include ﬂurbi-
profen, piroxicam and diclofenac (18,30). Salicylates
have much lower potencies and therefore are much
less likely to achieve therapeutic concentrations via
the topical route (18).
Efﬁcacy of topical NSAID therapy
NSAIDs primarily inhibit the COX pathway respon-
sible for transforming arachidonic acid to prosta-
glandins, prostacyclins and thromboxanes (7). A
meta-analysis in 2004 by Mason et al. (31) showed
topical NSAIDs to be effective and safe in treating
acute painful conditions for 1 week. This systemic
review of 26 double-blind, placebo-controlled trials
showed clinically signiﬁcant efﬁcacy in 19 of 26 tri-
als, with a pooled relative beneﬁt of 1.6 and number
needed to treat of 3.8 vs. placebo to achieve an out-
come of approximately 50% reduction in pain at
7 days (31). Results were consistent regardless of
end-point reported and condition treated (31). Three
trials (N = 433) that compared topical vs. oral NSA-
IDs showed similar efﬁcacy (31). Local AEs (4% top-
ical, 5% placebo), systemic AEs (3% topical, 2%
placebo) and withdrawals because of AEs (topical
and placebo both 1%) were not statistically different
from placebo (31). Vaile et al. (32) summarised dou-
ble-blind trials of topical NSAIDs vs. topical placebo
for soft tissue injuries. Topical NSAIDs that showed
a signiﬁcant beneﬁt with regard to pain control
included 2.5% niﬂumic acid gel (33) and ketorolac
gel (34). Several topical agents, including ketoprofen
2.5% gel, indomethacin 1% spray and ibuprofen 5%
gel, did not show signiﬁcant beneﬁt vs. placebo in
pain or function; in many cases, however, trends in
pain improvement favouring the active agent were
evident (32).
Safety of topical NSAIDs
Topical NSAIDs may have potential advantages when
compared with oral NSAIDs. Several studies demon-
strate that, perhaps because of low systemic concen-
trations, topical NSAIDs have a reduced risk of
upper GI complications such as gastric and peptic
ulcers, and GI nuisance symptoms such as dyspepsia
(23,35,36), as well as a lack of drug–drug interactions
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However, although AE incidence is low, larger con-
trolled, head-to-head comparisons of topical and oral
NSAIDs should be conducted to conﬁrm any safety
beneﬁt. Dose titration is often not needed with topi-
cal NSAIDs, thus reducing the time to effective pain
control (29). In addition, the ease of use of a topical
NSAID, as well as the subjective beneﬁt associated
with applying a topical preparation to a painful site,
may result in better acceptance by patients and a
possible increase in compliance (18). When given a
choice, many elderly patients with mild, transient
knee pain tend to choose topical NSAIDs over oral
NSAIDs (37–39). An exploratory analysis of factors
that inﬂuence patient choice of therapy found risk of
AEs, level and extent of pain, clinician’s advice and
convenience to contribute to patient preferences;
patients with transient pain were more likely to pre-
fer topical formulations for the short-term manage-
ment of pain (39).
Topical NSAIDs have been licenced for nearly
30 years in Europe, Japan and South Africa (25). A
large variety of topical NSAID formulations are avail-
able (24,32), ranging from ointments and creams to
gels and patches (Table 1). Topical NSAIDs have
now been introduced in the United States. Ongoing
and recently completed clinical trials of topical
NSAIDs in the United States include topical diclofe-
nac for the treatment of knee osteoarthritis (phase 3;
Nuvo Research Inc., Mississauga, ON, Canada) and
ketoprofen topical patch (20%) for the treatment of
pain associated with osteoarthritis ﬂare of the knee
(phase 3; Endo Pharmaceuticals, Chadds Ford, PA,
USA) (40,41).
The diclofenac epolamine topical patch 1.3%
One of the topical NSAID formulations approved in
the United States is the DETP. In contrast to other
conventional formulations (e.g. creams, gels), DETP
provides a deﬁned dose to a deﬁned area of skin for
12 h, requiring twice per day application (10). DETP
has recently been approved for use in the United
States for the topical treatment of acute pain caused
by minor strains, sprains and contusions (10).
Compound characteristics
DETP, marketed as FLECTOR
  Patch (King Phar-
maceuticals
 , Inc., Bridgewater, NJ, USA), developed
and patented by IBSA Institut Biochimique SA
(Lugano, Switzerland) (42) is the ﬁrst NSAID topical
patch available in the United States. Diclofenac epol-
amine is also known as diclofenac-N-(2-hydroxyeth-
yl)-pyrrolidine (DHEP) (10,43). The diclofenac
molecule, in its acidic form, is hydrophobic with
very low solubility in water (43). Studies have shown
that the epolamine salt of diclofenac has greater solu-
bility in water and non-polar solvents (1-octanol)
than other diclofenac salts that have been studied
(43,44). High concentrations of aqueous diclofenac
epolamine solutions exhibit surfactant behaviour
(43). The solubility and surfactant properties of
diclofenac epolamine enhance its membrane perme-
ability (43,44).
Mechanism of action
DETP is a ready-to-use adhesive patch composed of
two layers: an outer layer of non-woven polyester
felt backing and an adhesive inner layer containing
1.3% of diclofenac epolamine in a polymeric hydro-
gel (Figure 1) (10). The entire patch is covered with
a polypropylene ﬁlm-release liner that is removed
prior to application of the patch to the skin (10).
The felt backing prevents the hydrogel from drying
out and also hydrates the covered area of skin
during perspiration to aid in the absorption of active
ingredient. Whether the patch is used at rest or dur-
ing moderate exercise, there are no clinically relevant
differences in diclofenac plasma concentrations (10).
When applied to intact skin, the hydrogel enables
gradual and sustained release of the active agent into
the skin to provide local analgesia over a 12-h
period (10).
The anti-inﬂammatory, analgesic and antipyretic
actions of diclofenac are well established (45,46). It is
the most widely prescribed, traditional NSAID with
more than 30 years of clinical use (42,47). The char-
acterisation of diclofenac as a traditional NSAID,
inhibiting both COX-1 and COX-2, was further con-
ﬁrmed in a recent randomised controlled clinical
Table 1 Topical NSAID formulations available
worldwide (24,32)
Active ingredient Formulation(s)
Diclofenac Patch*, gel*, drops*
Indomethacin Ointment, spray, gel
Ibuprofen Cream, gel
Benzydamine Cream
Salicylic acid Cream, gel
Flurbiprofen Patch, drops
Piroxicam Gel
Felbinac Gel, foam
Eltenac Gel
Ketoprofen Gel, foam
Ketorolac Drops
Suprofen Drops
*Formulation of diclofenac approved in the United States.
NSAID, non-steroidal anti-inﬂammatory drug.
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ecoxib in healthy subjects (48). Sodium or potassium
salts of diclofenac are used in preparations for oral
administration and the diethylammonium and
sodium salt have been used in topical gel form
(42,49). Penetration of diclofenac into the muscular
tissue underlying the patch after application of DETP
has been indirectly demonstrated by the resulting sig-
niﬁcant increase of the muscular pain threshold (35).
Pharmacokinetics and metabolism
Absorption
Low systemic absorption of diclofenac following
DETP application has been shown in a study by Rusca
et al. (50). Over 12 h, the steady state plasma con-
centrations of diclofenac following DETP application
(twice daily for four consecutive days) were < 1% of
those following a single 50-mg oral dose of diclofe-
nac sodium (50). Based on two additional studies
assessing the pharmacokinetics of diclofenac potas-
sium over 6 h, the relative bioavailability of DETP
was estimated to be 0.9–1.7% of 75 mg diclofenac
potassium (51–53).
Other studies show that following a single applica-
tion of DETP on the upper area of the inner arm,
peak plasma concentrations of diclofenac (range:
0.7–6 ng⁄ml) were noted between 10 and 20 h after
application (10). Plasma concentrations of diclofenac
in the range of 1.3–8.8 ng⁄ml were noted after
5 days with twice-daily DETP application (10).
Gallacchi et al. (54) assessed blood and synovial lev-
els of diclofenac after repeated application of DETP
twice daily for four consecutive days in patients with
joint effusion (N = 8). Synovial ﬂuid concentrations
of diclofenac were 36% of concentrations found in
plasma. These concentrations indicate direct trans-
port of diclofenac across the skin to reach the syno-
vial ﬂuid compartment. The mean plasma
concentration was 3.62 ng⁄ml at 4 h after the last
application (54). Steady state plasma diclofenac con-
centrations evaluated in healthy subjects in three
studies between 1998 and 2002 were achieved before
day 3 and were approximately 3 ng⁄ml (51). During
12 h of DETP application, cycling for 20 min⁄h did
not affect the pharmacokinetic proﬁle of diclofenac
(51). Gschwend et al. (2005) (55) assessed blood
concentrations of diclofenac after twice-daily applica-
tion of DETP for four consecutive days in healthy
volunteers (N = 24). The maximum peak plasma
concentrations were 1.55 ng⁄ml (0–12 h) and
1.57 ng⁄ml (0–24 h) (55). These results can be com-
pared with studies of oral diclofenac sodium
reviewed by Brogden et al. (1980) (46). In a study
using an oral diclofenac sodium single dose of
25 mg, peak plasma concentrations of 720–
1100 ng⁄ml were reported in Geiger et al. (1975)
(56). In another study, an oral diclofenac sodium
Figure 1 Diagrammatic representation of the diclofenac epolamine topical patch at the site of application
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< 22 years) and older (age > 62 years) women; mean
peak plasma concentrations in this study were 1500–
1600 ng⁄ml (Willis and Kendall 1978) (57).
Distribution
Diclofenac is highly bound to serum proteins (46)
and has a very high afﬁnity (> 99%) for human
serum albumin (10). A low volume of distribution
allows for preferential distribution to the site of
inﬂammation and persistent concentrations in the
synovial ﬂuid, often with greater concentrations than
those found in plasma (58,59).
Metabolism and excretion
The plasma elimination half-life of diclofenac after
application of DETP is approximately 12 h (10).
Diclofenac is eliminated through metabolism and
subsequent urinary and biliary excretion of the
glucuronide and the sulphate conjugates of the
metabolites (10).
Clinical efﬁcacy
Soft tissue injuries
The efﬁcacy of DETP has been demonstrated in a
number of studies for the treatment of strains and
sprains. Jenoure et al. (60) performed an open-label
study of 101 patients with minor sports injuries.
Overall, treatment was associated with a 61% reduc-
tion in pain on pressure and a 60% reduction in
spontaneous pain [verbal and visual analog scale
(VAS)] after 2 weeks of DETP treatment (60). Anal-
gesic effects were apparent on day 7, with a mean
28% reduction of spontaneous pain (60). As judged
by the investigators, all but 18 patients (17.8%)
received clinical beneﬁt treatment. Global assess-
ments for tolerability of DETP, expressed by the
investigator and patients, were ‘good’ or ‘excellent’
in all patients studied (60). A multicenter, double-
blind, placebo-controlled study (N = 140) demon-
strated the effectiveness and tolerability of DETP vs.
placebo in reducing the acute pain of ankle sprain
(61). A signiﬁcant reduction in spontaneous pain
was observed for DETP vs. placebo starting at 3 h
(p = 0.005) and persisting until days 3 (p = 0.004)
and 7 (p = 0.0008). DETP was assessed as being
superior to placebo by both patients and physicians
and showed favourable local tolerability compared
with placebo. Joussellin (62) conducted a conﬁrma-
tory, multicenter, randomised, placebo-controlled,
parallel-group study in patients with acute ankle
sprain using comparable methodology. Patients
(N = 134) who sustained an ankle sprain < 48 h
before study entry and with spontaneous pain of at
least 50 mm on a 1- to 100-mm VAS were treated
with DETP, applied every morning for the 7-day
study period (62). DETP showed signiﬁcantly greater
efﬁcacy in the primary criteria, pain on movement,
when compared with placebo from the fourth hour
following the ﬁrst application until the end of the
study (62). All secondary criteria (pain at rest, pain
on passive stretch, pain on pressure, pain while lean-
ing on single foot) were signiﬁcantly improved from
day 3 in the DETP group compared with the placebo
group (62). Global judgment of efﬁcacy by both
patients and investigators conﬁrmed the superior
efﬁcacy of DETP vs. placebo (62). No adverse events
(AEs) were observed. Joussellin concluded that the
anti-inﬂammatory and analgesic properties of DETP,
combined with its local tolerability and ease of use,
make it a therapeutically useful treatment option for
minor ankle sprains (62). Rowbotham et al. (63)
evaluated the efﬁcacy and safety of DETP in the
treatment of minor sports injuries. Compared with
placebo, time to pain resolution [8.8 days (95% Con-
ﬁdence Interval, CI: 7.5–10.3) vs. 12.4 days (CI: 10.3,
> 15 days)] and reduction in pain scores (starting
day 6 and continuing to day 13, p = 0.042) were sig-
niﬁcantly better after administration of DETP
(q12 h) in subjects with acute pain caused by minor
sports injuries (63).
Galer et al. (36) studied the efﬁcacy and tolerabil-
ity of DETP vs. placebo for the treatment of
sports-related, soft tissue injuries (strains, sprains or
contusions) in a multicenter, randomised, parallel-
group, 2-week study (N = 222). DETP achieved
statistically signiﬁcant pain relief vs. placebo as mea-
sured by summed pain intensity difference at days 3
(p = 0.036) and 14 (p = 0.048) (36). As measured by
daily diaries, total pain relief scores and patient-rated
functional improvement scores were signiﬁcantly
higher with DETP compared with placebo at days 7
and 14 (p £ 0.037). There was no difference in pain
on pressure between groups. A similar incidence of
AEs was observed in both treatment groups (36).
Other conditions
Although DETP is indicated in the United States for
the treatment of acute pain caused by minor strains,
sprains and contusions, in other countries it has been
used for treatment of pain caused by other condi-
tions including osteoarthritis (10,64–66). Osteoar-
thritis Research Society International 2008
recommends use of topical NSAIDs for treatment of
knee osteoarthritis (67). Jenoure et al. (68) studied
the efﬁcacy of DETP in epicondylitis (tendinopathic
pathology) for a 2-week period with a 2-week post-
treatment follow-up. This was a multicenter, double-
blind, randomised, placebo-controlled study in 85
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in reducing spontaneous pain measured using a 5-
point verbal scale. At day 28, the percentage of
patients experiencing moderate-to-severe pain was
17.9% in the DETP group vs. 47.3% in the placebo
group (p < 0.01) (68).
Rosenthal et al. (69) compared DETP, applied
twice daily, with diclofenac diethylammonium
(DDA) emulgel, applied four times daily, in patients
(N = 190) with localised inﬂammatory diseases. In
this controlled, randomised, 2-week study both treat-
ments decreased pain; however, signiﬁcantly more
patients and investigators reported superior efﬁcacy
with DETP than with DDA (p < 0.001). The authors
theorised that better results were because of the con-
stant release of active substance by DETP vs. the
DDA emulgel, as the latter required four applications
daily. Both treatments were well tolerated (69).
Safety and tolerability
The most common AEs reported with DETP are
mild local skin reactions; topical NSAIDs, including
DETP, should not be applied to skin with lesions or
dermatologic conditions. In addition, topical
NSAIDs, like all NSAIDs, have a black box warning
for increased risk of cardiovascular events and seri-
ous GI AEs (10). Pooled safety data were evaluated
from 17 clinical trials with a total of 1344 patients
receiving 22,949 patches (average exposure 15.3
patches per patient) (70,71). The tolerability of
DETP was evaluated using the incidence of skin irri-
tation phenomena, sensitisation, phototoxicity
and⁄or photoallergy (70). Of the 1344 patients, only
43 (3.1%) had several moderate cutaneous reactions
consisting of erythema, pruritus or petechiae; no
serious local or systemic manifestations were
observed (70,71). Across clinical trials, the most
common AEs were skin reactions at the site of treat-
ment and were similar for DETP and placebo. These
included (DETP vs. placebo): pruritus (5% vs. 8%);
dermatitis (2% vs. < 1%) and burning (< 1% vs.
1%). Only 3% of patients in both the DETP and pla-
cebo patch groups discontinued treatment as a result
of an AE (10). In an analysis of data from 1997 to
1999 on the use of DETP twice daily for a minimum
of 14 days in children aged 8–15 years with minor
sports injuries, there were no reported AEs (72).
Approximately 175,000,000 patches have been dis-
pensed in over 40 countries around the world, repre-
senting over six million unique patient exposures.
Based on postmarketing reports from Europe and
the United States, covering June 1993 to January
2008, 178 AEs have been reported in 108 patients,
most commonly related to application site reactions
(71).
Conclusions
Increasing awareness of the AEs associated with oral
traditional NSAID therapy and coxibs has led many
physicians and patients to reconsider use of these
drugs despite their efﬁcacy for the management of
mild-to-moderate pain. One alternative has been to
develop ways to improve the safety of NSAIDs with-
out diminishing their efﬁcacy. These efforts include
the introduction of topical NSAID formulations,
which have been used as clinically effective analgesic
agents in Europe and throughout the world for
almost 30 years and are now approved for use in the
United States.
In contrast to conventional formulations, such as
creams, gels and sprays, DETP provides a deﬁned dose
to a deﬁned area for an extended period of time (typi-
cally 12 h), as opposed to topical NSAID gels or
creams that are applied up to four times daily (11,12).
Application of a cream or gel is at the discretion and
capability of the patient, and the dosage may depend
to some extent on diligence in following treatment
instructions. In addition, application of the patch is
devoid of the messiness or staining of the skin that
may occur while applying creams or gels. Both physi-
cian and patient global assessment data from clinical
trials were very favourable for DETP (60–62,68,69).
Topical NSAID formulations may be important for
patients who are at risk for GI AEs that may result
from the use of oral NSAIDs, because topical NSAIDs
expose patients to lower systemic levels of diclofenac.
Risk factors for serious GI events include older age,
prednisone use, previous NSAID GI side effects and
prior GI hospitalisation (73). Some patients, even
those without identiﬁable risk factors, may be familiar
with the risks associated with oral NSAIDs and may
simply prefer the low systemic exposure associated
with DETP use. In addition, although less serious, GI
AEs such as dyspepsia are among the most prevalent
AEs leading to discontinuation of oral NSAID therapy.
Reducing these nuisance AEs can lead to increased tol-
erability, compliance and patient satisfaction.
Many clinicians and patients are familiar with
patch formulations. For example, the lidocaine patch
has demonstrated efﬁcacy in the treatment of neuro-
pathic pain types, mainly by stabilising neuronal
activity, without signiﬁcant side effects (26). Topical
patches offer a local route of administration for
NSAIDs, which have both analgesic and anti-inﬂam-
matory properties. The different indications for these
patches are reﬂective of the potential differences in
mechanisms of action. In addition, other formula-
tions, such as liquids, foams, gels and creams, are
likely to offer advantages for patients with pain in
areas not amenable to patch application.
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effort dedicated towards optimising delivery of
NSAIDs while minimising associated risks, along
with an increased acceptance of topical formulations.
It is likely that additional topical analgesic formula-
tions will be introduced, and more clinical studies
will be performed both in support of these applica-
tions and in light of the new evidence about the risks
of oral NSAIDs.
Placebo-controlled studies included in the present
report found that patients treated with DETP experi-
enced a signiﬁcantly faster and greater improvement
in pain compared with patients treated with placebo.
Taking into consideration the safety proﬁle of topical
diclofenac formulations in general, and diclofenac
epolamine in particular, as well as the low incidence
of local adverse reactions and lack of systemic side
effects, DETP offers a viable treatment option in
patients presenting with acute pain caused by minor
strains, sprains and contusions.
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